论文部分内容阅读
目的观察并分析黄葵胶囊联合低分子肝素治疗儿童原发性肾病综合症的临床疗效。方法选取2010年3月～2012年3月期间某院收治的原发性肾病综合症儿童107例,随机分成2组,实验组(n=54)和对照组(n=53),实验组患儿在三联疗法上加用黄葵胶囊治疗,对照组仅采用四联疗法治疗,治疗2个月,观察记录患儿治疗前后24h尿蛋白等血清指标,观察记录患儿开始利尿和尿蛋白转阴时间。结果实验组24h蛋白尿、血清白蛋白、TC以及TG等指标的改善率(84.07%,74.24%,37.69%,53.89%)均明显高于对照组(53.57%,35.42%,21.47%,31.77%),差异有统计学意义(P﹤0.05);实验组患儿开始利尿时间和尿蛋白转阴时间(9.65±4.76,13.64±6.55)d均明显少于对照组(17.34±6.35,20.53±3.63)d,差异有统计学意义(P﹤0.05)。结论黄葵胶囊联合低分子肝素治疗儿童原发性肾病综合症的临床效果良好,起效快,症状改善明显,是值得临床大力推广应用的。
Objective To observe and analyze the clinical efficacy of Huang Kui capsule combined with low molecular weight heparin in the treatment of children with primary nephrotic syndrome. Methods A total of 107 children with primary nephrotic syndrome admitted from March 2010 to March 2012 in our hospital were randomly divided into two groups: experimental group (n = 54) and control group (n = 53) Children triple therapy with Huang Kui capsule treatment, the control group only treated with quadruple therapy for 2 months, observed and recorded 24h before and after treatment of children with urinary protein and other serum indicators to observe the record of children with diuretic and urine protein negative time. Results The improvement rates of proteinuria, serum albumin, TC and TG in the experimental group were significantly higher than those in the control group (53.57%, 35.42%, 21.47%, 31.77%, 84.07%, 74.24%, 37.69%, 53.89% ), The difference was statistically significant (P <0.05). The diuretic time and urine protein negative time in the experimental group (9.65 ± 4.76, 13.64 ± 6.55) d were significantly less than those in the control group (17.34 ± 6.35, 20.53 ± 3.63 ) d, the difference was statistically significant (P <0.05). Conclusion Huang Kui capsule combined with low molecular weight heparin in children with primary nephrotic syndrome clinical effect is good, rapid onset, obvious improvement of symptoms, is worthy of clinical promotion.